Trial: 202006133

A phase 1b/2 dose escalation and expansion study of tucatinib in combination with trastuzumab and oxaliplatin-based chemotherapy for HER2+ gastrointestinal cancers

Phase

I/II

Principal Investigator

Park, Haeseong

Disease Site

Colon; Esophagus; Other Digestive Organ; Rectum; Stomach

Learn more about this study at: clinicaltrials.gov